Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
SHR-4394 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
SHR-4394: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Egg-based H5N8 influenza vaccine (Sanofi Pasteur, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Egg-based H5N8 influenza vaccine (Sanofi Pasteur, Inc.): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development.
8 min read
JDB-153 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
JDB-153: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
![[11C]CPPC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_12_7f0c44f64f.jpg)
8 min read
[11C]CPPC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
[11C]CPPC: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Adipose derived autologous mesenchymal stem cell therapy (Celltex Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Adipose derived autologous mesenchymal stem cell therapy (Celltex Therapeutics): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
4SCAR-CD38 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
4SCAR-CD38: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
NBM-BMX Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
NBM-BMX: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
GNC-038 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
GNC-038: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Umbilical Cord Mesenchymal Stem Cells(Shanghai East Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Umbilical Cord Mesenchymal Stem Cells(Shanghai East Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
Human retinal pigment epithelial cell therapy (Astellas Pharma) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Human retinal pigment epithelial cell therapy (Astellas Pharma): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
Donor-derived Natural Killer Cell(Federal Research Institute of Pediatric Hematology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Donor-derived Natural Killer Cell(Federal Research Institute of Pediatric Hematology): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review.
8 min read
Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review.